Evolus News

Evolus Broadens International Presence With Launch of Nuceiva (Botulinum Toxin Type A) in Spain

Launching in one of the five largest aesthetic toxin injectable markets in Europe1 as part of the company's geographic expansion strategy Evolus to provide Nuceiva for direct order and delivery to Spanish

BusinesswireJun 12 08:00 ET

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 30,778

BusinesswireJun 7 17:00 ET

Evolus(EOLS.US) Officer Sells US$6.01 Million in Common Stock

$Evolus(EOLS.US)$ Officer MOATAZEDI DAVID sold 471.43K shares of common stock on Jun 4, 5, 6, 2024 at an average price of $12.7391 for a total value of $6.01 million.Source: Announcement What is state

moomoo NewsJun 6 19:45 ET

Form 144 | Evolus(EOLS.US) Officer Proposes to Sell 2.54 Million in Common Stocks

SEC FILLINGS DISCLOSED/ Jun 6, $Evolus(EOLS.US)$ Officer MOATAZEDI DAVID intends to sell 200K shares of its common stock on Jun 6, with a total market value of approximately $2.54 million. MOATAZEDI

moomoo NewsJun 6 17:47 ET

Evolus(EOLS.US) Director Sells US$97,203 in Common Stock

$Evolus(EOLS.US)$ Director Malik Vikram sold 7,500 shares of common stock on Jun 3, 2024 at an average price of $12.9604 for a total value of $97,203.Source: Announcement What is statement of changes

moomoo NewsJun 5 22:10 ET

Form 144 | Evolus(EOLS.US) Officer Proposes to Sell 1.97 Million in Common Stocks

SEC FILLINGS DISCLOSED/ Jun 5, $Evolus(EOLS.US)$ Officer MOATAZEDI DAVID intends to sell 155.28K shares of its common stock on Jun 5, with a total market value of approximately $1.97 million. MOATAZ

moomoo NewsJun 5 17:27 ET

Form 144 | Evolus(EOLS.US) Officer Proposes to Sell 1.78 Million in Common Stocks

SEC FILLINGS DISCLOSED/ Jun 4, $Evolus(EOLS.US)$ Officer MOATAZEDI DAVID intends to sell 140.21K shares of its common stock on Jun 4, with a total market value of approximately $1.78 million. MOATAZ

moomoo NewsJun 4 16:56 ET

Evolus, Inc. (NASDAQ:EOLS) Not Lagging Industry On Growth Or Pricing

With a price-to-sales (or "P/S") ratio of 3.6x Evolus, Inc. (NASDAQ:EOLS) may be sending bearish signals at the moment, given that almost half of all Pharmaceuticals companies in the United States hav

Simply Wall StMay 27 08:33 ET

Barclays Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $16

Barclays analyst Balaji Prasad maintains $Evolus(EOLS.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 46.3% and a total aver

moomoo NewsMay 24 05:33 ET

Barclays Reaffirms Their Buy Rating on Evolus (EOLS)

TipRanksMay 24 05:27 ET

Strong Buy Rating for Evolus Backed by Growth Potential and Market Penetration Prospects

TipRanksMay 22 00:35 ET

Evolus (EOLS) Releases Favorable Dermal Fillers Study Data

Yahoo FinanceMay 21 10:57 ET

Evolus Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/21/2024 101.19% HC Wainwright & Co. → $27 Reiterates Buy → Buy 05/08/2024 101.19% HC Wainwright & Co. →

BenzingaMay 21 06:37 ET

Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Korro Bio (KRRO) and Inhibikase Therapeutics (IKT)

TipRanksMay 21 06:20 ET

Express News | Evolus Dermal Filler Evolysse Lift Meets Primary Endpoint, Demonstrates Superiority To Restylane-L At 6 Months; Shows Statistically Significant Improvement In Nasolabial Fold Severity Compared To Restylane-L At All Timepoints Over 12 Months

BenzingaMay 20 08:31 ET

Evolus Announces Positive Data From Pivotal Trial for First Two Evolysse Dermal Filler Products at 2024 SCALE Meeting

Evolus dermal filler, Evolysse Lift, met primary endpoint of non-inferiority and demonstrated superiority to Restylane-L at 6 months; Secondary endpoints for improvement in nasolabial fold severity s

BusinesswireMay 20 08:30 ET

Director David Gill Sells 10,361 Shares of Evolus Inc (EOLS)

Yahoo FinanceMay 16 02:54 ET

Evolus(EOLS.US) Director Sells US$362.01K in Common Stock

$Evolus(EOLS.US)$ Director Malik Vikram sold 28,000 shares of common stock on May 13, 2024 at an average price of $12.929 for a total value of $362.01K.Source: Announcement What is statement of change

moomoo NewsMay 15 17:59 ET

Evolus(EOLS.US) Director Sells US$131.01K in Common Stock

$Evolus(EOLS.US)$ Director GILL DAVID N sold 10,361 shares of common stock on May 13, 14, 2024 at an average price of $12.6445 for a total value of $131.01K.Source: Announcement What is statement of c

moomoo NewsMay 15 17:59 ET

Evolus Celebrates Fifth Anniversary of Launching Its Flagship Product Jeuveau at the Women's Wear Daily Beauty CEO Summit

David Moatazedi, President and Chief Executive Officer of Evolus, is first medical aesthetics leader to be a speaker at WWD Beauty CEO Summit Evolus' flagship product, Jeuveau is the fastest growing

BusinesswireMay 15 08:30 ET